Cargando…

FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients

BACKGROUND: Careful selection of malignant pleural mesothelioma (MPM) patients for curative treatment is of highest importance, as the multimodal treatment regimen is challenging for patients and harbors a high risk of substantial toxicity. Radiomics—a quantitative method for image analysis—has show...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavic, M., Bogowicz, M., Kraft, J., Vuong, D., Mayinger, M., Kroeze, S. G. C., Friess, M., Frauenfelder, T., Andratschke, N., Huellner, M., Weder, W., Guckenberger, M., Tanadini-Lang, S., Opitz, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359199/
https://www.ncbi.nlm.nih.gov/pubmed/32661672
http://dx.doi.org/10.1186/s13550-020-00669-3
_version_ 1783558999686250496
author Pavic, M.
Bogowicz, M.
Kraft, J.
Vuong, D.
Mayinger, M.
Kroeze, S. G. C.
Friess, M.
Frauenfelder, T.
Andratschke, N.
Huellner, M.
Weder, W.
Guckenberger, M.
Tanadini-Lang, S.
Opitz, I.
author_facet Pavic, M.
Bogowicz, M.
Kraft, J.
Vuong, D.
Mayinger, M.
Kroeze, S. G. C.
Friess, M.
Frauenfelder, T.
Andratschke, N.
Huellner, M.
Weder, W.
Guckenberger, M.
Tanadini-Lang, S.
Opitz, I.
author_sort Pavic, M.
collection PubMed
description BACKGROUND: Careful selection of malignant pleural mesothelioma (MPM) patients for curative treatment is of highest importance, as the multimodal treatment regimen is challenging for patients and harbors a high risk of substantial toxicity. Radiomics—a quantitative method for image analysis—has shown its prognostic ability in different tumor entities and could therefore play an important role in optimizing patient selection for radical cancer treatment. So far, radiomics as a prognostic tool in MPM was not investigated. MATERIALS AND METHODS: This study is based on 72 MPM patients treated with surgery in a curative intent at our institution between 2009 and 2017. Pre-treatment Fluorine-18 fluorodeoxyglucose (FDG) PET and CT scans were used for radiomics outcome modeling. After extraction of 1404 CT and 1410 FDG PET features from each image, a preselection by principal component analysis was performed to include only robust, non-redundant features for the cox regression to predict the progression-free survival (PFS) and the overall survival (OS). Results were validated on a separate cohort. Additionally, SUVmax and SUVmean, and volume were tested for their prognostic ability for PFS and OS. RESULTS: For the PFS a concordance index (c-index) of 0.67 (95% CI 0.52–0.82) and 0.66 (95% CI 0.57–0.78) for the training cohort (n = 36) and internal validation cohort (n = 36), respectively, were obtained for the PET radiomics model. The PFS advantage of the low-risk group translated also into an OS advantage. On CT images, no radiomics model could be trained. SUV max and SUV mean were also not prognostic in terms of PFS and OS. CONCLUSION: We were able to build a successful FDG PET radiomics model for the prediction of PFS in MPM. Radiomics could serve as a tool to aid clinical decision support systems for treatment of MPM in future.
format Online
Article
Text
id pubmed-7359199
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-73591992020-07-16 FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients Pavic, M. Bogowicz, M. Kraft, J. Vuong, D. Mayinger, M. Kroeze, S. G. C. Friess, M. Frauenfelder, T. Andratschke, N. Huellner, M. Weder, W. Guckenberger, M. Tanadini-Lang, S. Opitz, I. EJNMMI Res Original Research BACKGROUND: Careful selection of malignant pleural mesothelioma (MPM) patients for curative treatment is of highest importance, as the multimodal treatment regimen is challenging for patients and harbors a high risk of substantial toxicity. Radiomics—a quantitative method for image analysis—has shown its prognostic ability in different tumor entities and could therefore play an important role in optimizing patient selection for radical cancer treatment. So far, radiomics as a prognostic tool in MPM was not investigated. MATERIALS AND METHODS: This study is based on 72 MPM patients treated with surgery in a curative intent at our institution between 2009 and 2017. Pre-treatment Fluorine-18 fluorodeoxyglucose (FDG) PET and CT scans were used for radiomics outcome modeling. After extraction of 1404 CT and 1410 FDG PET features from each image, a preselection by principal component analysis was performed to include only robust, non-redundant features for the cox regression to predict the progression-free survival (PFS) and the overall survival (OS). Results were validated on a separate cohort. Additionally, SUVmax and SUVmean, and volume were tested for their prognostic ability for PFS and OS. RESULTS: For the PFS a concordance index (c-index) of 0.67 (95% CI 0.52–0.82) and 0.66 (95% CI 0.57–0.78) for the training cohort (n = 36) and internal validation cohort (n = 36), respectively, were obtained for the PET radiomics model. The PFS advantage of the low-risk group translated also into an OS advantage. On CT images, no radiomics model could be trained. SUV max and SUV mean were also not prognostic in terms of PFS and OS. CONCLUSION: We were able to build a successful FDG PET radiomics model for the prediction of PFS in MPM. Radiomics could serve as a tool to aid clinical decision support systems for treatment of MPM in future. Springer Berlin Heidelberg 2020-07-13 /pmc/articles/PMC7359199/ /pubmed/32661672 http://dx.doi.org/10.1186/s13550-020-00669-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Research
Pavic, M.
Bogowicz, M.
Kraft, J.
Vuong, D.
Mayinger, M.
Kroeze, S. G. C.
Friess, M.
Frauenfelder, T.
Andratschke, N.
Huellner, M.
Weder, W.
Guckenberger, M.
Tanadini-Lang, S.
Opitz, I.
FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients
title FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients
title_full FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients
title_fullStr FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients
title_full_unstemmed FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients
title_short FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients
title_sort fdg pet versus ct radiomics to predict outcome in malignant pleural mesothelioma patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359199/
https://www.ncbi.nlm.nih.gov/pubmed/32661672
http://dx.doi.org/10.1186/s13550-020-00669-3
work_keys_str_mv AT pavicm fdgpetversusctradiomicstopredictoutcomeinmalignantpleuralmesotheliomapatients
AT bogowiczm fdgpetversusctradiomicstopredictoutcomeinmalignantpleuralmesotheliomapatients
AT kraftj fdgpetversusctradiomicstopredictoutcomeinmalignantpleuralmesotheliomapatients
AT vuongd fdgpetversusctradiomicstopredictoutcomeinmalignantpleuralmesotheliomapatients
AT mayingerm fdgpetversusctradiomicstopredictoutcomeinmalignantpleuralmesotheliomapatients
AT kroezesgc fdgpetversusctradiomicstopredictoutcomeinmalignantpleuralmesotheliomapatients
AT friessm fdgpetversusctradiomicstopredictoutcomeinmalignantpleuralmesotheliomapatients
AT frauenfeldert fdgpetversusctradiomicstopredictoutcomeinmalignantpleuralmesotheliomapatients
AT andratschken fdgpetversusctradiomicstopredictoutcomeinmalignantpleuralmesotheliomapatients
AT huellnerm fdgpetversusctradiomicstopredictoutcomeinmalignantpleuralmesotheliomapatients
AT wederw fdgpetversusctradiomicstopredictoutcomeinmalignantpleuralmesotheliomapatients
AT guckenbergerm fdgpetversusctradiomicstopredictoutcomeinmalignantpleuralmesotheliomapatients
AT tanadinilangs fdgpetversusctradiomicstopredictoutcomeinmalignantpleuralmesotheliomapatients
AT opitzi fdgpetversusctradiomicstopredictoutcomeinmalignantpleuralmesotheliomapatients